查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1433658

病毒载体/质体DNA 製造市场规模、份额和趋势分析报告：按载体类型、工作流程、应用、最终用途、疾病、地区和细分市场进行预测，2024-2030 年

Viral Vector And Plasmid DNA Manufacturing Market Size, Share & Trends Analysis Report By Vector Type (AAV, Lentivirus), By Workflow, By Application, By End-use, By Disease, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

病毒载体和质体DNA 製造市场的成长和趋势：

Grand View Research, Inc.最新报告预测，到2030年，全球病毒载体和质体DNA製造市场规模预计将达到195亿美元，2024年至2030年复合年增长率为20.2%。

随着基因疗法对质体DNA 和病毒载体的需求增加，产业领导者正在引入新技术来提高质体DNA 的生产。例如，2018年4月，GE医疗生命科学宣布推出KUBio BSL 2，这是一种预製模组化生物加工设施，用于生产基于病毒载体的溶瘤病毒、细胞和基因治疗以及免疫学。

随着细胞和基因治疗研究领域的投资增加，市场对病毒载体的需求空前。因此，各个组织正在提供资金来加速这些载体的製造流程的发展。例如，2019年9月，加拿大下一代製造公司向iVexSol Canada主导的联盟提供了189万美元。这笔资金用于开发慢病毒载体的先进製造流程。 2iVexSol Canada 是一家向量製造公司，与多家公司合作开发先进的 LVV 製造平台。

此外，在这个市场上营运的主要企业，包括 Thermo Fisher Scientific、QIAGEN NV、Agilent Technologies、Takara Bio 和 Oxford Biomedica，都专注于开发新的基因转移平台。这些公司正在进行大量投资，扩大生物基因转移系统的生产，以满足不断增长的市场需求。例如，2020年5月，Takara Bio在滋贺县完成了基因和细胞治疗处理II中心（CGCPII）的建造。该中心是该公司 GMP 病毒载体生产设施的补充。同样，赛默飞世尔科技于 2020 年 5 月投资 1.8 亿美元，将其病毒载体生产能力提高了一倍。预计此类倡议的增加将在预测期内推动市场成长。

此外，病毒载体的大规模生产面临上游工程的挑战。在上游工程中，生产病毒载体的方法是製造商的主要障碍之一。大规模复製贴壁细胞培养是一个需要解决的重要问题。因此，研究人员正在尝试使用大型反应器来培养这些细胞。此外，需要更了解下游加工中这些载体的纯度。

病毒载体和质体DNA 製造市场报告亮点：

  • 根据载体类型，由于高需求和临床试验中使用量的增加，腺结合病毒(AAV) 细分市场在 2023 年占据市场主导地位，销售份额为 20.0%。
  • 基于工作流程，下游处理领域在工作流程领域中占据最大的收益占有率，并由于下游处理技术的进步和一次性系统的采用而在2023年引领市场。
  • 从应用来看，疫苗治疗领域预计将在 2023 年以最大的收益占有率主导市场，而细胞治疗预计在预测期内将以最快的复合年增长率成长。
  • 以最终用途划分，研究机构细分市场占据主导地位，到 2023 年收益占有率最大。另一方面，製药和生物製药公司预计在预测期内将以最快的复合年增长率成长。
  • 按疾病划分，肿瘤领域预计将在 2023 年以最大的收益占有率主导市场，并在预测期内以最快的复合年增长率增长。
  • 北美由于癌症和感染疾病负担高、购买力平价高、政府对优质医疗保健的支持以及可报销等因素在市场上占据主导地位。

目录

第一章调查方法和范围

第 2 章执行摘要

第 3 章 病毒载体和质体DNA 製造市场的变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 病毒载体/质体DNA製造市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • COVID-19 影响分析

第 4 章 病毒载体/质体DNA 製造市场：载体类型估计与趋势分析

  • 按载体类型分類的全球病毒载体和质体DNA 製造市场前景
  • 腺结合病毒（AAV）
  • 慢病毒
  • 腺病毒
  • 逆转录病毒
  • 质体
  • 其他的

第五章病毒载体/质体DNA製造市场：工作流程估计与趋势分析

  • 按工作流程分類的全球病毒载体和质体DNA 製造市场前景
  • 上游加工
  • 下游加工

第六章 病毒载体/质体DNA製造市场：使用量估算与趋势分析

  • 全球病毒载体与质体DNA製造市场（依应用）展望
  • 基因治疗
  • 细胞疗法
  • 疫苗
  • 研究用途

第 7 章 病毒载体/质体DNA 製造市场：最终用途估计与趋势分析

  • 按最终用途分類的全球病毒载体和质体DNA 製造市场前景
  • 製药公司/生物製药公司
  • 研究机构

第八章病毒载体/质体DNA製造市场：疾病估计与趋势分析

  • 按疾病分類的全球病毒载体和质体DNA 製造市场展望
  • 癌症
  • 遗传疾病
  • 感染疾病
  • 其他的

第九章病毒载体/质体DNA製造市场：区域估计与趋势分析

  • 2023 年及 2030 年区域市场占有率分析
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第10章竞争形势

  • 公司分类
  • 策略规划
  • 2023 年企业市场分析
  • 公司简介/名单
    • Merck KGaA
    • Lonza
    • FUJIFILM Diosynth Biotechnologies
    • Thermo Fisher Scientific
    • Cobra Biologics
    • Catalent Inc.
    • Wuxi Biologics
    • Takara Bio Inc.
    • Waisman Biomanufacturing
    • Genezen laboratories
    • Batavia Biosciences
    • Miltenyi Biotec GmbH
    • SIRION Biotech GmbH
    • Virovek Incorporation
    • BioNTech IMFS GmbH
    • Audentes Therapeutics
    • BioMarin Pharmaceutical
    • RegenxBio, Inc.
Product Code: GVR-2-68038-695-0

Viral Vector And Plasmid DNA Manufacturing Market Growth & Trends:

The global viral vector and plasmid DNA manufacturing market size is anticipated to reach USD 19.5 billion by 2030 and it is projected to grow at a CAGR of 20.2% from 2024 - 2030, according to a new report by Grand View Research, Inc. With the increasing demand for plasmid DNA and viral vectors for gene therapy, industry leaders have launched new technologies to boost plasmid DNA manufacturing. For instance, in April 2018, GE Healthcare Life Sciences introduced KUBio BSL 2, a prefabricated, modular bioprocessing facility for the production of oncolytic viruses, cell and gene treatments, and immunizations based on viral vectors.

With the increase in investments in cell and gene therapy research space, there is unprecedented demand for viral vectors in the market. Owing to this, various organizations are providing funds to accelerate developments in the manufacturing processes for these vectors. For instance, in September 2019, Next Generation Manufacturing Canada provided USD 1.89 million to a consortium led by iVexSol Canada. This fund was provided for the development of an advanced manufacturing process for lentiviral vectors. 2iVexSol Canada is a vector manufacturing company that has collaborated with several companies to develop an advanced LVV manufacturing platform.

Moreover, the major companies operating in this market, such as Thermo Fisher Scientific, QIAGEN NV, Agilent Technologies, Takara Bio, Inc., and Oxford Biomedica, are focusing on developing new gene delivery platforms. These companies are making huge investments to scale up the production of biological gene delivery systems to meet the increasing market demand. For instance, in May 2020, Takara Bio, Inc. completed the Center for Gene and Cell Therapy Processing II (CGCPII) construction in Shiga, Japan. This center is an addition to its GMP viral vector production facility. Similarly, in May 2020, Thermo Fisher Scientific also invested USD 180 million to scale up its viral vector manufacturing capacity twofold. Such increasing initiatives are anticipated to propel market growth in the forecast period.

Furthermore, large-scale production of viral vectors is facing challenges in upstream and downstream processing. In upstream processes, the method used for viral vector production is one of the major hurdles for manufacturers. Reproduction of adherent cell cultures at a large scale is a key concern that needs to be addressed. Thus, researchers are trying to grow these cells using large bioreactors. In addition, there is a need for a better understanding of the purity of these vectors in downstream processing.

Viral Vector And Plasmid DNA Manufacturing Market Report Highlights:

  • Based on the vector type, the adeno-associated virus (AAV) segment dominated the market with a 20.0% revenue share in 2023 due to high demand, and their usage in clinical trials is growing
  • Based on the workflow, the downstream processing segment led the market in 2023 with the largest revenue share in workflow segment due to advancements in downstream processing technologies and the adoption of single-use systems
  • Based on the application, the vaccinology segment dominated the application segment in 2023 with the largest revenue share, and cell therapy is expected to grow at fastest CAGR during the forecast period
  • Based on the end-use, the research institutes segment dominated the market with the largest revenue share in 2023. On the other hand, the pharmaceutical and biopharmaceutical companies are expected to grow at a fastest CAGR over the forecast period
  • In terms of disease, the cancer segment dominated the market with the largest revenue share in 2023 and it is anticipated to grow at fastest CAGR during the forecast period
  • North America dominated the market owing to factors such as the significant burden of cancer, and infectious diseases, high purchasing power parity, government support for quality healthcare, and availability of reimbursement

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Vector type
    • 1.2.2. Workflow
    • 1.2.3. Application
    • 1.2.4. End-use
    • 1.2.5. Disease
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Viral Vectors And Plasmid DNA Manufacturing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Robust Pipeline for Gene Therapies and Viral Vector Vaccines
      • 3.2.1.2. Technological Advancements in Manufacturing Vectors
      • 3.2.1.3. Highly Competitive Market and Various Strategies Undertaken by Market Entities
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Regulatory, Scientific, And Ethical Challenges Associated With Gene Therapy And Viral Vectors
  • 3.3. Viral Vectors And Plasmid DNA Manufacturing Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Viral Vectors And Plasmid DNA Manufacturing Market: Vector Type Estimates & Trend Analysis

  • 4.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by Vector Type Outlook
  • 4.2. Adeno-associated virus (AAV)
    • 4.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
  • 4.3. Lentivirus
    • 4.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
  • 4.4. Adenovirus
    • 4.4.1. Market estimates and forecasts 2018 to 2030, (USD Million)
  • 4.5. Retrovirus
    • 4.5.1. Market estimates and forecasts 2018 to 2030, (USD Million)
  • 4.6. Plasmids
    • 4.6.1. Market estimates and forecasts 2018 to 2030, (USD Million)
  • 4.7. Others
    • 4.7.1. Market estimates and forecasts 2018 to 2030, (USD Million)

Chapter 5. Viral Vectors And Plasmid DNA Manufacturing Market: Workflow Estimates & Trend Analysis

  • 5.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by Workflow Outlook
  • 5.2. Upstream Manufacturing
    • 5.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
    • 5.2.2. Vector Amplification & Expansion
      • 5.2.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
    • 5.2.3. Vector Recovery/Harvesting
      • 5.2.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
  • 5.3. Downstream Manufacturing
    • 5.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
    • 5.3.2. Purification
      • 5.3.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
    • 5.3.3. Fill Finish diagnostic instruments
      • 5.3.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)

Chapter 6. Viral Vectors And Plasmid DNA Manufacturing Market: Application Estimates & Trend Analysis

  • 6.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by Application Outlook
  • 6.2. Gene Therapy
    • 6.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.3. Cell Therapy
    • 6.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.4. Vaccinology
    • 6.4.1. Market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.5. Research Applications
    • 6.5.1. Market estimates and forecasts 2018 to 2030, (USD Million)

Chapter 7. Viral Vectors And Plasmid DNA Manufacturing Market: End-use Estimates & Trend Analysis

  • 7.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by End-use Outlook
  • 7.2. Pharmaceutical and Biopharmaceutical Companies
    • 7.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
  • 7.3. Research Institutes
    • 7.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)

Chapter 8. Viral Vectors And Plasmid DNA Manufacturing Market: Disease Estimates & Trend Analysis

  • 8.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by Disease Outlook
  • 8.2. Cancer
    • 8.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.3. Genetic Disorders
    • 8.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.4. Infectious Diseases
    • 8.4.1. Market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.5. Other
    • 8.5.1. Market estimates and forecasts 2018 to 2030, (USD Million)

Chapter 9. Viral Vectors And Plasmid DNA Manufacturing Market: Regional Estimates & Trend Analysis

  • 9.1. Regional Market Share Analysis, 2023 & 2030
  • 9.2. North America
    • 9.2.1. North America market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.2.2. U.S.
      • 9.2.2.1. Key country dynamics
      • 9.2.2.2. Regulatory framework
      • 9.2.2.3. Competitive scenario
      • 9.2.2.4. U.S. market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.2.2.5. Target disease prevalence
    • 9.2.3. Canada
      • 9.2.3.1. Key country dynamics
      • 9.2.3.2. Regulatory framework
      • 9.2.3.3. Competitive scenario
      • 9.2.3.4. Canada market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.2.3.5. Target disease prevalence
  • 9.3. Europe
    • 9.3.1. Europe market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.3.2. UK
      • 9.3.2.1. Key country dynamics
      • 9.3.2.2. Regulatory framework
      • 9.3.2.3. Competitive scenario
      • 9.3.2.4. UK market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.3.2.5. Target disease prevalence
    • 9.3.3. Germany
      • 9.3.3.1. Key country dynamics
      • 9.3.3.2. Regulatory framework
      • 9.3.3.3. Competitive scenario
      • 9.3.3.4. Germany market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.3.3.5. Target disease prevalence
    • 9.3.4. France
      • 9.3.4.1. Key country dynamics
      • 9.3.4.2. Regulatory framework
      • 9.3.4.3. Competitive scenario
      • 9.3.4.4. France market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.3.4.5. Target disease prevalence
    • 9.3.5. Italy
      • 9.3.5.1. Key country dynamics
      • 9.3.5.2. Regulatory framework
      • 9.3.5.3. Competitive scenario
      • 9.3.5.4. Italy market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.3.5.5. Target disease prevalence
    • 9.3.6. Spain
      • 9.3.6.1. Key country dynamics
      • 9.3.6.2. Regulatory framework
      • 9.3.6.3. Competitive scenario
      • 9.3.6.4. Spain market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.3.6.5. Target disease prevalence
    • 9.3.7. Norway
      • 9.3.7.1. Key country dynamics
      • 9.3.7.2. Regulatory framework
      • 9.3.7.3. Competitive scenario
      • 9.3.7.4. Norway market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.3.7.5. Target disease prevalence
    • 9.3.8. Sweden
      • 9.3.8.1. Key country dynamics
      • 9.3.8.2. Regulatory framework
      • 9.3.8.3. Competitive scenario
      • 9.3.8.4. Sweden market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.3.8.5. Target disease prevalence
    • 9.3.9. Denmark
      • 9.3.9.1. Key country dynamics
      • 9.3.9.2. Regulatory framework
      • 9.3.9.3. Competitive scenario
      • 9.3.9.4. Denmark market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.3.9.5. Target disease prevalence
  • 9.4. Asia Pacific
    • 9.4.1. Asia Pacific market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.4.2. Japan
      • 9.4.2.1. Key country dynamics
      • 9.4.2.2. Regulatory framework
      • 9.4.2.3. Competitive scenario
      • 9.4.2.4. Japan market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.4.2.5. Target disease prevalence
    • 9.4.3. China
      • 9.4.3.1. Key country dynamics
      • 9.4.3.2. Regulatory framework
      • 9.4.3.3. Competitive scenario
      • 9.4.3.4. China market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.4.3.5. Target disease prevalence
    • 9.4.4. India
      • 9.4.4.1. Key country dynamics
      • 9.4.4.2. Regulatory framework
      • 9.4.4.3. Competitive scenario
      • 9.4.4.4. India market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.4.4.5. Target disease prevalence
    • 9.4.5. Australia
      • 9.4.5.1. Key country dynamics
      • 9.4.5.2. Regulatory framework
      • 9.4.5.3. Competitive scenario
      • 9.4.5.4. Australia market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.4.5.5. Target disease prevalence
    • 9.4.6. South Korea
      • 9.4.6.1. Key country dynamics
      • 9.4.6.2. Regulatory framework
      • 9.4.6.3. Competitive scenario
      • 9.4.6.4. South Korea market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.4.6.5. Target disease prevalence
    • 9.4.7. Thailand
      • 9.4.7.1. Key country dynamics
      • 9.4.7.2. Regulatory framework
      • 9.4.7.3. Competitive scenario
      • 9.4.7.4. Thailand market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.4.7.5. Target disease prevalence
  • 9.5. Latin America
    • 9.5.1. Latin America market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.5.2. Brazil
      • 9.5.2.1. Key country dynamics
      • 9.5.2.2. Regulatory framework
      • 9.5.2.3. Competitive scenario
      • 9.5.2.4. Brazil market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.5.2.5. Target disease prevalence
    • 9.5.3. Mexico
      • 9.5.3.1. Key country dynamics
      • 9.5.3.2. Regulatory framework
      • 9.5.3.3. Competitive scenario
      • 9.5.3.4. Mexico market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.5.3.5. Target disease prevalence
    • 9.5.4. Argentina
      • 9.5.4.1. Key country dynamics
      • 9.5.4.2. Regulatory framework
      • 9.5.4.3. Competitive scenario
      • 9.5.4.4. Argentina market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.5.4.5. Target disease prevalence
  • 9.6. MEA
    • 9.6.1. MEA market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.6.2. South Africa
      • 9.6.2.1. Key country dynamics
      • 9.6.2.2. Regulatory framework
      • 9.6.2.3. Competitive scenario
      • 9.6.2.4. South Africa market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.6.2.5. Target disease prevalence
    • 9.6.3. Saudi Arabia
      • 9.6.3.1. Key country dynamics
      • 9.6.3.2. Regulatory framework
      • 9.6.3.3. Competitive scenario
      • 9.6.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.6.3.5. Target disease prevalence
    • 9.6.4. UAE
      • 9.6.4.1. Key country dynamics
      • 9.6.4.2. Regulatory framework
      • 9.6.4.3. Competitive scenario
      • 9.6.4.4. UAE market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.6.4.5. Target disease prevalence
    • 9.6.5. Kuwait
      • 9.6.5.1. Key country dynamics
      • 9.6.5.2. Regulatory framework
      • 9.6.5.3. Competitive scenario
      • 9.6.5.4. Kuwait market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.6.5.5. Target disease prevalence

Chapter 10. Competitive Landscape

  • 10.1. Company Categorization
  • 10.2. Strategy Mapping
  • 10.3. Company Market Position Analysis, 2023
  • 10.4. Company Profiles/Listing
    • 10.4.1. Merck KGaA
      • 10.4.1.1. Company overview
      • 10.4.1.2. Financial performance
      • 10.4.1.3. Product benchmarking
      • 10.4.1.4. Strategic initiatives
    • 10.4.2. Lonza
      • 10.4.2.1. Company overview
      • 10.4.2.2. Financial performance
      • 10.4.2.3. Product benchmarking
      • 10.4.2.4. Strategic initiatives
    • 10.4.3. FUJIFILM Diosynth Biotechnologies
      • 10.4.3.1. Company overview
      • 10.4.3.2. Financial performance
      • 10.4.3.3. Product benchmarking
      • 10.4.3.4. Strategic initiatives
    • 10.4.4. Thermo Fisher Scientific
      • 10.4.4.1. Company overview
      • 10.4.4.2. Financial performance
      • 10.4.4.3. Product benchmarking
      • 10.4.4.4. Strategic initiatives
    • 10.4.5. Cobra Biologics
      • 10.4.5.1. Company overview
      • 10.4.5.2. Financial performance
      • 10.4.5.3. Product benchmarking
      • 10.4.5.4. Strategic initiatives
    • 10.4.6. Catalent Inc.
      • 10.4.6.1. Company overview
      • 10.4.6.2. Financial performance
      • 10.4.6.3. Product benchmarking
      • 10.4.6.4. Strategic initiatives
    • 10.4.7. Wuxi Biologics
      • 10.4.7.1. Company overview
      • 10.4.7.2. Financial performance
      • 10.4.7.3. Product benchmarking
      • 10.4.7.4. Strategic initiatives
    • 10.4.8. Takara Bio Inc.
      • 10.4.8.1. Company overview
      • 10.4.8.2. Financial performance
      • 10.4.8.3. Product benchmarking
      • 10.4.8.4. Strategic initiatives
    • 10.4.9. Waisman Biomanufacturing
      • 10.4.9.1. Company overview
      • 10.4.9.2. Financial performance
      • 10.4.9.3. Product benchmarking
      • 10.4.9.4. Strategic initiatives
    • 10.4.10. Genezen laboratories
      • 10.4.10.1. Company overview
      • 10.4.10.2. Financial performance
      • 10.4.10.3. Product benchmarking
      • 10.4.10.4. Strategic initiatives
    • 10.4.11. Batavia Biosciences
      • 10.4.11.1. Company overview
      • 10.4.11.2. Financial performance
      • 10.4.11.3. Product benchmarking
      • 10.4.11.4. Strategic initiatives
    • 10.4.12. Miltenyi Biotec GmbH
      • 10.4.12.1. Company overview
      • 10.4.12.2. Financial performance
      • 10.4.12.3. Product benchmarking
      • 10.4.12.4. Strategic initiatives
    • 10.4.13. SIRION Biotech GmbH
      • 10.4.13.1. Company overview
      • 10.4.13.2. Financial performance
      • 10.4.13.3. Product benchmarking
      • 10.4.13.4. Strategic initiatives
    • 10.4.14. Virovek Incorporation
      • 10.4.14.1. Company overview
      • 10.4.14.2. Financial performance
      • 10.4.14.3. Product benchmarking
      • 10.4.14.4. Strategic initiatives
    • 10.4.15. BioNTech IMFS GmbH
      • 10.4.15.1. Company overview
      • 10.4.15.2. Financial performance
      • 10.4.15.3. Product benchmarking
      • 10.4.15.4. Strategic initiatives
    • 10.4.16. Audentes Therapeutics
      • 10.4.16.1. Company overview
      • 10.4.16.2. Financial performance
      • 10.4.16.3. Product benchmarking
      • 10.4.16.4. Strategic initiatives
    • 10.4.17. BioMarin Pharmaceutical
      • 10.4.17.1. Company overview
      • 10.4.17.2. Financial performance
      • 10.4.17.3. Product benchmarking
      • 10.4.17.4. Strategic initiatives
    • 10.4.18. RegenxBio, Inc.
      • 10.4.18.1. Company overview
      • 10.4.18.2. Financial performance
      • 10.4.18.3. Product benchmarking
      • 10.4.18.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America viral vector and plasmid DNA manufacturing market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 4 North America viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 5 North America viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 6 North America viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 7 North America viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 8 U.S. viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 9 U.S. viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 10 U.S. viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 11 U.S. viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 12 U.S. viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 13 Canada viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 14 Canada viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 15 Canada viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 16 Canada viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 17 Canada viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 18 Europe viral vector and plasmid DNA manufacturing market, by region, 2018 - 2030 (USD Million)
  • Table 19 Europe viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 20 Europe viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 21 Europe viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 22 Europe viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 23 Europe viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 24 UK viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 25 UK viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 26 UK viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 27 UK viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 28 UK viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 29 Germany viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 30 Germany viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 31 Germany viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 32 Germany viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 33 Germany viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 34 France viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 35 France viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 36 France viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 37 France viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 38 France viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 39 Spain viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 40 Spain viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 41 Spain viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 42 Spain viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 43 Spain viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 44 Italy viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 45 Italy viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 46 Italy viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 47 Italy viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 48 Italy viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 49 Denmark viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 50 Denmark viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 51 Denmark viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 52 Denmark viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 53 Denmark viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 54 Sweden viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 55 Sweden viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 56 Sweden viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 57 Sweden viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 58 Sweden viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 59 Norway viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 60 Norway viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 61 Norway viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 62 Norway viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 63 Norway viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 64 Asia Pacific viral vector and plasmid DNA manufacturing market, by region, 2018 - 2030 (USD Million)
  • Table 65 Asia Pacific viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 66 Asia Pacific viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 67 Asia Pacific viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 68 Asia Pacific viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 69 Asia Pacific viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 70 Japan viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 71 Japan viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 72 Japan viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 73 Japan viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 74 Japan viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 75 China viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 76 China viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 77 China viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 78 China viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 79 China viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 80 India viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 81 India viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 82 India viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 83 India viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 84 India viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 85 South Korea viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 86 South Korea viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 87 South Korea viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 88 South Korea viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 89 South Korea viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 90 Australia viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 91 Australia viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 92 Australia viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 93 Australia viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 94 Australia viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 95 Thailand viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 96 Thailand viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 97 Thailand viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 98 Thailand viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 99 Thailand viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 100 Latin America viral vector and plasmid DNA manufacturing market, by region, 2018 - 2030 (USD Million)
  • Table 101 Latin America viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 102 Latin America viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 103 Latin America viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 104 Latin America viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 105 Latin America viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 106 Brazil viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 107 Brazil viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 108 Brazil viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 109 Brazil viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 110 Brazil viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 111 Mexico viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 112 Mexico viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 113 Mexico viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 114 Mexico viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 115 Mexico viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 116 Argentina viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 117 Argentina viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 118 Argentina viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 119 Argentina viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 120 Argentina viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 121 Middle East and Africa viral vector and plasmid DNA manufacturing market, by region, 2018 - 2030 (USD Million)
  • Table 122 Middle East and Africa viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 123 Middle East and Africa viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 124 Middle East and Africa viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 125 Middle East and Africa viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 126 Middle East and Africa viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 127 South Africa viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 128 South Africa viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 129 South Africa viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 130 South Africa viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 131 South Africa viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 132 Saudi Arabia viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 133 Saudi Arabia viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 134 Saudi Arabia viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 135 Saudi Arabia viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 136 Saudi Arabia viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 137 UAE viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 138 UAE viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 139 UAE viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 140 UAE viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 141 UAE viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 142 Kuwait viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 143 Kuwait viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 144 Kuwait viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 145 Kuwait viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 146 Kuwait viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Viral vector and plasmid DNA manufacturing market: market outlook
  • Fig. 9 Viral vector and plasmid DNA manufacturing competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Viral vector and plasmid DNA manufacturing market driver impact
  • Fig. 15 Viral vector and plasmid DNA manufacturing market restraint impact
  • Fig. 16 Viral vector and plasmid DNA manufacturing market strategic initiatives analysis
  • Fig. 17 Viral vector and plasmid DNA manufacturing market: Vector type movement analysis
  • Fig. 18 Viral vector and plasmid DNA manufacturing market: Vector type outlook and key takeaways
  • Fig. 19 Adenovirus market estimates and forecast, 2018 - 2030
  • Fig. 20 Retrovirus market estimates and forecast, 2018 - 2030
  • Fig. 21 Adeno-Associated Virus (AAV)market estimates and forecast, 2018 - 2030
  • Fig. 22 Lentivirus market estimates and forecast, 2018 - 2030
  • Fig. 23 Plasmids market estimates and forecast, 2018 - 2030
  • Fig. 24 Others market estimates and forecast, 2018 - 2030
  • Fig. 25 Viral vector and plasmid DNA manufacturing market: Workflow movement Analysis
  • Fig. 26 Viral vector and plasmid DNA manufacturing market: Workflow outlook and key takeaways
  • Fig. 27 Upstream manufacturing market estimates and forecasts, 2018 - 2030
  • Fig. 28 Vector amplification & expansion market estimates and forecasts, 2018 - 2030
  • Fig. 29 Vector recovery/harvesting market estimates and forecasts, 2018 - 2030
  • Fig. 30 Downstream manufacturing market estimates and forecasts, 2018 - 2030
  • Fig. 31 Purification market estimates and forecasts, 2018 - 2030
  • Fig. 32 Fill finish market estimates and forecasts, 2018 - 2030
  • Fig. 33 Viral vector and plasmid DNA manufacturing market: Application movement Analysis
  • Fig. 34 Viral vector and plasmid DNA manufacturing market: Application outlook and key takeaways
  • Fig. 35 Antisense & RNAi therapy market estimates and forecasts, 2018 - 2030
  • Fig. 36 Gene Therapy market estimates and forecasts, 2018 - 2030
  • Fig. 37 Cell Therapy market estimates and forecasts, 2018 - 2030
  • Fig. 38 Vaccinology market estimates and forecasts, 2018 - 2030
  • Fig. 39 Research Applications market estimates and forecasts, 2018 - 2030
  • Fig. 40 Viral vector and plasmid DNA manufacturing market: End-use movement Analysis
  • Fig. 41 Viral vector and plasmid DNA manufacturing market: End-use outlook and key takeaways
  • Fig. 42 Pharmaceutical and biopharmaceutical companies market estimates and forecasts, 2018 - 2030
  • Fig. 43 Research institutes market estimates and forecasts, 2018 - 2030
  • Fig. 44 Viral vector and plasmid DNA manufacturing market: Disease movement Analysis
  • Fig. 45 Viral vector and plasmid DNA manufacturing market: Disease outlook and key takeaways
  • Fig. 46 Cancer market estimates and forecasts, 2018 - 2030
  • Fig. 47 Genetic disorders market estimates and forecasts, 2018 - 2030
  • Fig. 48 Infectious Diseases market estimates and forecasts, 2018 - 2030
  • Fig. 49 Others market estimates and forecasts, 2018 - 2030
  • Fig. 50 Global viral vector and plasmid DNA manufacturing market: Regional movement analysis
  • Fig. 51 Global viral vector and plasmid DNA manufacturing market: Regional outlook and key takeaways
  • Fig. 52 Global viral vector and plasmid DNA manufacturing market share and leading players
  • Fig. 53 North America, by country
  • Fig. 54 North America
  • Fig. 55 North America market estimates and forecasts, 2018 - 2030
  • Fig. 56 U.S.
  • Fig. 57 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 58 Canada
  • Fig. 59 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 60 Europe
  • Fig. 61 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 62 UK
  • Fig. 63 UK market estimates and forecasts, 2018 - 2030
  • Fig. 64 Germany
  • Fig. 65 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 66 France
  • Fig. 67 France market estimates and forecasts, 2018 - 2030
  • Fig. 68 Italy
  • Fig. 69 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 70 Spain
  • Fig. 71 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 72 Denmark
  • Fig. 73 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 74 Sweden
  • Fig. 75 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 76 Norway
  • Fig. 77 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 78 Asia Pacific
  • Fig. 79 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 80 China
  • Fig. 81 China market estimates and forecasts, 2018 - 2030
  • Fig. 82 Japan
  • Fig. 83 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 84 India
  • Fig. 85 India market estimates and forecasts, 2018 - 2030
  • Fig. 86 Thailand
  • Fig. 87 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 88 South Korea
  • Fig. 89 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 90 Australia
  • Fig. 91 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 92 Latin America
  • Fig. 93 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 94 Brazil
  • Fig. 95 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 96 Mexico
  • Fig. 97 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 98 Argentina
  • Fig. 99 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 100 Middle East and Africa
  • Fig. 101 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 102 South Africa
  • Fig. 103 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 104 Saudi Arabia
  • Fig. 105 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 106 UAE
  • Fig. 107 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 108 Kuwait
  • Fig. 109 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 110 Market share of key market players- Viral vector and plasmid DNA manufacturing market